Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
|
MOA & AR: Methotrexate
|
Inhibit thymidine synthesis (dTMP)
S-phase specific antimetabolite Folic acid analog: inhibit DHF reductase Myelosuppression: reversible w/ leucovorin rescue (folinic acid) Macrovesicular fatty change in liver Mucositis |
|
|
MOA & AR: 5-FU
|
Inhibit thymidine synthesis (dTMP)
S-phase specific antimetabolite Pyrimidine analog: inhibit thymidilate synthase Myelosuppression: irreversible Photosensitivity (Rescue w/ thymidine) |
|
|
2 Antimetabolites
S-phase specific |
1. MTX
2. 5-FU |
|
|
MOA & AR: 6-MP
|
Inhibit purine synthesis
Activated by HGPRTase Bone marrow, GI, liver Higher toxicity w/ allopurinol (metabolized by xanthine oxidase) |
|
|
3 Nucleotide Synthesis Inhibitors
|
1. MTX
2. 5-FU 3. 6-MP |
|
|
5 DNA inhibiting agents
|
1. Alkyating agents
2. Cisplatin 3. Dactinomycin 4. Doxurubicin 5. Etoposide |
|
|
2 Cellular division inhibitors
|
1. Vinca alkaloids
2. Paclitaxel |
|
|
3 DNA cross-linkers
|
1. Alkylating agent: Busulfan
2. Alkylating agent: Cyclophosphamide 3. Cisplatin |
|
|
2 DNA intercalators
|
1. Dactinomycin
2. Doxorubicin |
|
|
Top II inhibitor
|
Etoposide
|
|
|
Purine synthesis inhibitor
|
6-MP
|
|
|
2 Thymidine synthesis inhibitors
|
1. MTX
2. 5-FU |
|
|
Microtubule formation inhibitor
|
Vinca alkaloids
|
|
|
Microtubule disassembly inhibitor
|
Paclitaxel
|
|
|
MOA & AR: Cisplatin, Carboplatin
|
DNA cross-linker
Nephrotox Ototoxicity |
|
|
MOA & AR: Cyclophosphamide
|
Alkylating agent
Interstrand x-linkage at guanine N7 (require liver bioactivation) Myelosuppression Hemorrhagic cystitis (prevent w/ mesna) |
|
|
2 Alkylating agents
|
1. Busulfan
2. Cyclophosphamide |
|
|
MOA & AR: Busulfan
|
Alkylates DNA
Pulmonary fibrosis Hyperpigmentation |
|
|
MOA & AR: Doxurubicin, Daunorubicin
|
DNA intercalator = breaks
Free radical generation Cardiomyopathy Myelosuppression Alopecia Toxic extravasation |
|
|
MOA & AR: Dactinomycin (Actinomycin D)
|
DNA intercalator
(Childhood tumors) Myelosuppression |
|
|
MOA & AR: Bleomycin
|
Free radical DNA damage
Pulmonary fibrosis Skin changes Minimial myelosuppresion |
|
|
MOA & AR: Etoposide (V-16)
|
Top II inhibitor
G2 phase-specific inhibitor DNA degradation Myelosuppression GI irritation Alopecia |
|
|
MOA & AR: Tamoxifen, Raloxifene
|
SERMs: receptor antagonist in breast, agonist in bone
Block estrogen binding Endometrial carcinoma Hot flashes *Raloxifene: endometrial antagonist = NO endometrial carcinoma |
|
|
MOA & AR: Trastuzumab (Herceptin)
|
Monoclonal antibody against HER-2 (breast cancer)
Cardiotixicity |
|
|
MOA & AR: Imantib (Gleevec)
|
bcr-abl tyrosine kinase inhibitor (Philadelphia chromosome)
Fluid retention |
|
|
MOA & AR: Vincristine, Vinblastine (Vinca alkaloids)
|
Inhibit microtubule formation
M-phase specific Vincristine: Neurotox (areflexia, peripheral neuritis) Paralytic ileus VinBLASTine: Bone marrow suppression (BLAST bone marrow) |
|
|
MOA & AR: Paclitaxel
|
Inhibit microtubule disassembly
M-phase specific agent: hyperstabilize --> NO anaphase Myelosuppression Hypersenstivity |
|
|
AR of Prednisone
|
Cushings
Hypertension Acne Immunosuppression Hyperglycemia Cataract Osteoporosis Peptic ulcers Psychosis |
